pan-serotype dengue virus NS4B inhibitor
oral preclin. candidate, trial planned
From 1.5M cmpd phenotypic screen + opt.
Sci. Transl. Med., Feb. 3, 2021
Novartis (NITD), Emeryville, CA
NITD-688
14. The Novartis pan-serotype dengue virus (DENV) NS4B protein inhibitor, NITD-688, is a preclinical candidate with strong activity against all four serotypes of DENV in vitro and excellent oral…